Literature DB >> 23371897

PPARγ: no SirT, no service.

Frederick W Quelle1, Curt D Sigmund.   

Abstract

Entities:  

Year:  2013        PMID: 23371897      PMCID: PMC3580855          DOI: 10.1161/CIRCRESAHA.113.300870

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  20 in total

1.  C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists.

Authors:  Cecile Vernochet; Sidney B Peres; Kathryn E Davis; Meghan E McDonald; Li Qiang; Hong Wang; Philipp E Scherer; Stephen R Farmer
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

2.  Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.

Authors:  I Barroso; M Gurnell; V E Crowley; M Agostini; J W Schwabe; M A Soos; G L Maslen; T D Williams; H Lewis; A J Schafer; V K Chatterjee; S O'Rahilly
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

3.  Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone.

Authors:  Leanne Wilson-Fritch; Sarah Nicoloro; My Chouinard; Mitchell A Lazar; Patricia C Chui; John Leszyk; Juerg Straubhaar; Michael P Czech; Silvia Corvera
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

4.  Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet.

Authors:  Andreas M Beyer; Willem J de Lange; Carmen M Halabi; Mary L Modrick; Henry L Keen; Frank M Faraci; Curt D Sigmund
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

5.  Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ.

Authors:  Li Qiang; Liheng Wang; Ning Kon; Wenhui Zhao; Sangkyu Lee; Yiying Zhang; Michael Rosenbaum; Yingming Zhao; Wei Gu; Stephen R Farmer; Domenico Accili
Journal:  Cell       Date:  2012-08-03       Impact factor: 41.582

6.  Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.

Authors:  Jill C Milne; Philip D Lambert; Simon Schenk; David P Carney; Jesse J Smith; David J Gagne; Lei Jin; Olivier Boss; Robert B Perni; Chi B Vu; Jean E Bemis; Roger Xie; Jeremy S Disch; Pui Yee Ng; Joseph J Nunes; Amy V Lynch; Hongying Yang; Heidi Galonek; Kristine Israelian; Wendy Choy; Andre Iffland; Siva Lavu; Oliver Medvedik; David A Sinclair; Jerrold M Olefsky; Michael R Jirousek; Peter J Elliott; Christoph H Westphal
Journal:  Nature       Date:  2007-11-29       Impact factor: 49.962

7.  Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human.

Authors:  Jun Wu; Pontus Boström; Lauren M Sparks; Li Ye; Jang Hyun Choi; An-Hoa Giang; Melin Khandekar; Kirsi A Virtanen; Pirjo Nuutila; Gert Schaart; Kexin Huang; Hua Tu; Wouter D van Marken Lichtenbelt; Joris Hoeks; Sven Enerbäck; Patrick Schrauwen; Bruce M Spiegelman
Journal:  Cell       Date:  2012-07-12       Impact factor: 41.582

8.  Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

Authors:  Paul A Dutchak; Takeshi Katafuchi; Angie L Bookout; Jang Hyun Choi; Ruth T Yu; David J Mangelsdorf; Steven A Kliewer
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

9.  Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.

Authors:  Silvie Timmers; Ellen Konings; Lena Bilet; Riekelt H Houtkooper; Tineke van de Weijer; Gijs H Goossens; Joris Hoeks; Sophie van der Krieken; Dongryeol Ryu; Sander Kersten; Esther Moonen-Kornips; Matthijs K C Hesselink; Iris Kunz; Vera B Schrauwen-Hinderling; Ellen Blaak; Johan Auwerx; Patrick Schrauwen
Journal:  Cell Metab       Date:  2011-11-02       Impact factor: 27.287

10.  Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.

Authors:  Jang Hyun Choi; Alexander S Banks; Theodore M Kamenecka; Scott A Busby; Michael J Chalmers; Naresh Kumar; Dana S Kuruvilla; Youseung Shin; Yuanjun He; John B Bruning; David P Marciano; Michael D Cameron; Dina Laznik; Michael J Jurczak; Stephan C Schürer; Dušica Vidović; Gerald I Shulman; Bruce M Spiegelman; Patrick R Griffin
Journal:  Nature       Date:  2011-09-04       Impact factor: 49.962

View more
  3 in total

Review 1.  PPARγ Regulation in Hypertension and Metabolic Syndrome.

Authors:  Madeliene Stump; Masashi Mukohda; Chunyan Hu; Curt D Sigmund
Journal:  Curr Hypertens Rep       Date:  2015-12       Impact factor: 5.369

2.  PPARγ Mediates the Anti-Epithelial-Mesenchymal Transition Effects of FGF1ΔHBS in Chronic Kidney Diseases via Inhibition of TGF-β1/SMAD3 Signaling.

Authors:  Dezhong Wang; Tianyang Zhao; Yushuo Zhao; Yuan Yin; Yuli Huang; Zizhao Cheng; Beibei Wang; Sidan Liu; Minling Pan; Difei Sun; Zengshou Wang; Guanghui Zhu
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

3.  PPARγ Deacetylation Confers the Antiatherogenic Effect and Improves Endothelial Function in Diabetes Treatment.

Authors:  Longhua Liu; Lihong Fan; Michelle Chan; Michael J Kraakman; Jing Yang; Yong Fan; Nicole Aaron; Qianfen Wan; Maria Alicia Carrillo-Sepulveda; Alan R Tall; Ira Tabas; Domenico Accili; Li Qiang
Journal:  Diabetes       Date:  2020-05-14       Impact factor: 9.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.